Back to results
US 2024/0190958 A1Published application
Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof
OwnerJonas Helma-Smets, Annette Vogl +7inventors
InventorsJonas Helma-Smets, Annette Vogl, Saskia Schmitt, Isabelle Mai, Sarah Herterich, Dominik Schumacher, Marc-André Kasper, Philipp Cyprys, Marcus Gerlach
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel anti-NaPi2b antibodies, novel antibody-drug-conjugates (ADCs) based thereon as well as to therapeutic methods and uses thereof, particularly in relation to cancer treatment.
Claims21
An antibody drug conjugate (ADC) comprising an anti-NaPi2b antibody, wherein said NaPi2b antibody is capable of the following:
- a) binding to human Napi2b and/or rat Napi2b;
- b) cross-reactivity with rat Napi2b;
- c) cross-reactivity with cynomolgus monkey Napi2b;
- d) internalization, optionally by the means of the antigen-mediated antibody internalization;
- and
- e) not having a dipeptide deamidation site in a heavy chain variable region's (VH) CDR2, optionally said absent dipeptide deamidation site is NG (Asn-Gly) in VH CDR2;
- wherein said anti-NaPi2b antibody is conjugated to one or more cytotoxic moieties.
4 more elements
Dependencies are inferred from the claim text.